Letters The story of anti-influenza drugs

Authors’ reply to Dunning

BMJ 2014; 348 doi: http://dx.doi.org/10.1136/bmj.g3018 (Published 30 April 2014) Cite this as: BMJ 2014;348:g3018
  1. Peter Doshi, assistant professor1,
  2. Tom Jefferson, reviewer2
  1. 1University of Maryland School of Pharmacy, Baltimore, MD, USA
  2. 2Cochrane Acute Respiratory Infections Group, 00187, Roma, Italy
  1. pdoshi{at}rx.umaryland.edu

Dunning questions the relevance of our systematic review, suggesting that any research data—regardless of its quality—that tests the effect of neuraminidase inhibitors on non-pandemic influenza answers the wrong question.1 2 Because all randomised trial evidence is on non-pandemic influenza, he argues that we must look elsewhere and highlights non-randomised observational studies, which conclude that the drugs provide great benefit, contrary to the conclusions that can be drawn from randomised trials.

This line of argument has …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe